Novavax settles COVID-19 vaccine dispute with Gavi Alliance

  • Investing.com
  • Stock Market News
Novavax settles COVID-19 vaccine dispute with Gavi Alliance
Credit: © Reuters.

GAITHERSBURG, Md. - Novavax , Inc. (NASDAQ: NVAX ) has concluded a settlement with Gavi, the Vaccine Alliance, resolving the arbitration stemming from the 2021 Advance Purchase Agreement for Novavax's COVID-19 vaccine, NVX-CoV2373. The settlement, announced today, includes a financial arrangement and a commitment to support equitable vaccine access in low-income nations.

Under the settlement terms, Novavax has paid Gavi $75 million upfront and agreed to deferred payments totaling $400 million through 2028. These payments are due quarterly, with the option for Novavax to offset or reduce the annual $80 million cash obligation through vaccine credits. These credits apply to qualifying sales of any of Novavax's vaccines funded by Gavi for supply to low and lower-middle-income countries. Additionally, Novavax may provide up to $225 million in extra vaccine credits in response to increased demand over the five-year term.

John C. Jacobs, President and CEO of Novavax, expressed satisfaction with the agreement, emphasizing the continued partnership with Gavi to ensure equitable vaccine access. David Marlow, Gavi's interim CEO, echoed this sentiment, highlighting the importance of the agreement for global immunization efforts and vaccine market health.

Novavax is recognized for its innovative vaccine technology, including its COVID-19 vaccine and a combined COVID-19 and influenza vaccine in development. Gavi, a public-private global health partnership, has been instrumental in immunizing children worldwide and enhancing health security through support for health systems and vaccine stockpiles.

The information in this article is based on a press release statement.

InvestingPro Insights

As Novavax, Inc. (NASDAQ:NVAX) progresses with its commitment to global health through the recent settlement with Gavi, the financial health of the company remains a focal point for investors. According to real-time data from InvestingPro, Novavax holds a market capitalization of $472.79 million, reflecting its standing in the biotechnology market. Despite the challenges faced, the company's liquidity position is noteworthy, as it holds more cash than debt on its balance sheet, which is a positive sign for its financial stability and ability to meet short-term obligations.

Nevertheless, the company's financial metrics indicate areas of concern. Novavax's revenue has seen a significant decline over the last twelve months as of Q3 2023, with a decrease of 43.15%. This trend is further highlighted by a quarterly revenue growth figure for Q3 2023 that fell by 74.55%. Additionally, the company's gross profit margin stands at -14.16%, signaling difficulties in maintaining profitability.

InvestingPro Tips reveal that analysts are not optimistic about the company's profitability in the near term, as they do not anticipate Novavax will be profitable this year. Moreover, the valuation multiple suggests that the stock is trading at a low revenue valuation, which could be a point of interest for value investors. For those seeking further insights and analysis, InvestingPro offers additional tips on Novavax, which can be accessed at https://www.investing.com/pro/NVAX. Readers can use the coupon code PRONEWS24 to receive an additional 10% off a yearly or biyearly Pro and Pro+ subscription, providing access to a total of 12 additional InvestingPro Tips that can help inform investment decisions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Drop an image here or Supported formats: *.jpg, *.png, *.gif up to 5mb

Error: File type not supported

Drop an image here or

100

Related Articles